← All trials
NCT03945357
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2019
- Primary completion
- May 15, 2021
- Completion date
- May 15, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Greenville Health SystemLead sponsor
- Washington University in St. LouisCollaborator
- University of PennsylvaniaCollaborator
- Oregon Health and Science UniversityCollaborator
- Ohio State UniversityCollaborator
- New Hanover Regional Medical CenterCollaborator
- The Cleveland ClinicCollaborator
- Pennsylvania State UniversityCollaborator
- Prisma HealthOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.